233 related articles for article (PubMed ID: 16682254)
1. Analysis of tumors arising in male B6C3F1 mice with and without AAV vector delivery to liver.
Bell P; Moscioni AD; McCarter RJ; Wu D; Gao G; Hoang A; Sanmiguel JC; Sun X; Wivel NA; Raper SE; Furth EE; Batshaw ML; Wilson JM
Mol Ther; 2006 Jul; 14(1):34-44. PubMed ID: 16682254
[TBL] [Abstract][Full Text] [Related]
2. Long-term correction of ammonia metabolism and prolonged survival in ornithine transcarbamylase-deficient mice following liver-directed treatment with adeno-associated viral vectors.
Moscioni D; Morizono H; McCarter RJ; Stern A; Cabrera-Luque J; Hoang A; Sanmiguel J; Wu D; Bell P; Gao GP; Raper SE; Wilson JM; Batshaw ML
Mol Ther; 2006 Jul; 14(1):25-33. PubMed ID: 16677864
[TBL] [Abstract][Full Text] [Related]
3. No evidence for tumorigenesis of AAV vectors in a large-scale study in mice.
Bell P; Wang L; Lebherz C; Flieder DB; Bove MS; Wu D; Gao GP; Wilson JM; Wivel NA
Mol Ther; 2005 Aug; 12(2):299-306. PubMed ID: 16043099
[TBL] [Abstract][Full Text] [Related]
4. AAV-encoded OTC activity persisting to adulthood following delivery to newborn spf(ash) mice is insufficient to prevent shRNA-induced hyperammonaemia.
Cunningham SC; Kok CY; Spinoulas A; Carpenter KH; Alexander IE
Gene Ther; 2013 Dec; 20(12):1184-7. PubMed ID: 24108150
[TBL] [Abstract][Full Text] [Related]
5. Adeno-associated virus-mediated delivery of IL-4 prevents collagen-induced arthritis.
Cottard V; Mulleman D; Bouille P; Mezzina M; Boissier MC; Bessis N
Gene Ther; 2000 Nov; 7(22):1930-9. PubMed ID: 11127581
[TBL] [Abstract][Full Text] [Related]
6. Vector-related tumorigenesis not found in ornithine transcarbamylase-deficient mice.
Koeberl DD
Mol Ther; 2006 Jul; 14(1):1-2. PubMed ID: 16750655
[No Abstract] [Full Text] [Related]
7. AAV gene therapy corrects OTC deficiency and prevents liver fibrosis in aged OTC-knock out heterozygous mice.
Wang L; Bell P; Morizono H; He Z; Pumbo E; Yu H; White J; Batshaw ML; Wilson JM
Mol Genet Metab; 2017 Apr; 120(4):299-305. PubMed ID: 28283349
[TBL] [Abstract][Full Text] [Related]
8. Increased efficacy and safety in the treatment of experimental liver cancer with a novel adenovirus-alphavirus hybrid vector.
Guan M; Rodriguez-Madoz JR; Alzuguren P; Gomar C; Kramer MG; Kochanek S; Prieto J; Smerdou C; Qian C
Cancer Res; 2006 Feb; 66(3):1620-9. PubMed ID: 16452221
[TBL] [Abstract][Full Text] [Related]
9. In vivo assessment of mutations in OTC for dominant-negative effects following rAAV2/8-mediated gene delivery to the mouse liver.
Ginn SL; Cunningham SC; Zheng M; Spinoulas A; Carpenter KH; Alexander IE
Gene Ther; 2009 Jun; 16(6):820-3. PubMed ID: 19357713
[TBL] [Abstract][Full Text] [Related]
10. Utility of intraperitoneal administration as a route of AAV serotype 5 vector-mediated neonatal gene transfer.
Ogura T; Mizukami H; Mimuro J; Madoiwa S; Okada T; Matsushita T; Urabe M; Kume A; Hamada H; Yoshikawa H; Sakata Y; Ozawa K
J Gene Med; 2006 Aug; 8(8):990-7. PubMed ID: 16685745
[TBL] [Abstract][Full Text] [Related]
11. Transient depletion of CD4 lymphocyte improves efficacy of repeated administration of recombinant adenovirus in the ornithine transcarbamylase deficient sparse fur mouse.
Ye X; Robinson MB; Pabin C; Batshaw ML; Wilson JM
Gene Ther; 2000 Oct; 7(20):1761-7. PubMed ID: 11083498
[TBL] [Abstract][Full Text] [Related]
12. Observed incidence of tumorigenesis in long-term rodent studies of rAAV vectors.
Donsante A; Vogler C; Muzyczka N; Crawford JM; Barker J; Flotte T; Campbell-Thompson M; Daly T; Sands MS
Gene Ther; 2001 Sep; 8(17):1343-6. PubMed ID: 11571571
[TBL] [Abstract][Full Text] [Related]
13. Induction and prevention of severe hyperammonemia in the spfash mouse model of ornithine transcarbamylase deficiency using shRNA and rAAV-mediated gene delivery.
Cunningham SC; Kok CY; Dane AP; Carpenter K; Kizana E; Kuchel PW; Alexander IE
Mol Ther; 2011 May; 19(5):854-9. PubMed ID: 21386824
[TBL] [Abstract][Full Text] [Related]
14. AAV serotype-1 mediates early onset of gene expression in mouse hearts and results in better therapeutic effect.
Su H; Huang Y; Takagawa J; Barcena A; Arakawa-Hoyt J; Ye J; Grossman W; Kan YW
Gene Ther; 2006 Nov; 13(21):1495-502. PubMed ID: 16775632
[TBL] [Abstract][Full Text] [Related]
15. Early, sustained efficacy of adeno-associated virus vector-mediated gene therapy in glycogen storage disease type Ia.
Koeberl DD; Sun BD; Damodaran TV; Brown T; Millington DS; Benjamin DK; Bird A; Schneider A; Hillman S; Jackson M; Beaty RM; Chen YT
Gene Ther; 2006 Sep; 13(17):1281-9. PubMed ID: 16672983
[TBL] [Abstract][Full Text] [Related]
16. In vivo high-efficiency transcoronary gene delivery and Cre-LoxP gene switching in the adult mouse heart.
Iwatate M; Gu Y; Dieterle T; Iwanaga Y; Peterson KL; Hoshijima M; Chien KR; Ross J
Gene Ther; 2003 Oct; 10(21):1814-20. PubMed ID: 12960971
[TBL] [Abstract][Full Text] [Related]
17. AAV2/8-mediated correction of OTC deficiency is robust in adult but not neonatal Spf(ash) mice.
Cunningham SC; Spinoulas A; Carpenter KH; Wilcken B; Kuchel PW; Alexander IE
Mol Ther; 2009 Aug; 17(8):1340-6. PubMed ID: 19384294
[TBL] [Abstract][Full Text] [Related]
18. Correction of ornithine transcarbamylase deficiency in adult spf(ash) mice and in OTC-deficient human hepatocytes with recombinant adenoviruses bearing the CAG promoter.
Kiwaki K; Kanegae Y; Saito I; Komaki S; Nakamura K; Miyazaki JI; Endo F; Matsuda I
Hum Gene Ther; 1996 May; 7(7):821-30. PubMed ID: 8860834
[TBL] [Abstract][Full Text] [Related]
19. A single injection of double-stranded adeno-associated viral vector expressing GH normalizes growth in GH-deficient mice.
Sagazio A; Xiao X; Wang Z; Martari M; Salvatori R
J Endocrinol; 2008 Jan; 196(1):79-88. PubMed ID: 18180319
[TBL] [Abstract][Full Text] [Related]
20. Gene therapy with novel adeno-associated virus vectors substantially diminishes atherosclerosis in a murine model of familial hypercholesterolemia.
Lebherz C; Gao G; Louboutin JP; Millar J; Rader D; Wilson JM
J Gene Med; 2004 Jun; 6(6):663-72. PubMed ID: 15170737
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
